QGEN Stock Analysis: Qiagen | NYSE

Diagnostics & Research | NYSE, USA | Market Cap: 9.455m USD | 12M Return: 2.8% | NL0015002SN0 | Charts, Fundamentals & Technical Analysis

Sample Preparation, Diagnostic Assays, PCR Instruments, Sequencing Products
Total Rating 51
Safety 91
Buy Signal -0.18
Diagnostics & Research
Industry Rotation: +7.2
Market Cap: 9.46B
Avg Turnover: 94.1M
Risk 3d forecast
Volatility28.3%
VaR 5th Pctl4.62%
VaR vs Median-0.85%
Reward TTM
Sharpe Ratio0.14
Rel. Str. IBD54.1
Rel. Str. Peer Group5.2
Character TTM
Beta0.336
Beta Downside0.207
Hurst Exponent0.572
Drawdowns 3y
Max DD41.38%
CAGR/Max DD0.22
CAGR/Mean DD0.86
EPS (Earnings per Share) EPS (Earnings per Share) of QGEN over the last years for every Quarter: "2021-09": 0.65, "2021-12": 0.83, "2022-03": 0.89, "2022-06": 0.57, "2022-09": 0.59, "2022-12": 0.59, "2023-03": 0.57, "2023-06": 0.57, "2023-09": 0.56, "2023-12": 0.6, "2024-03": 0.5, "2024-06": 0.6, "2024-09": 0.62, "2024-12": 0.64, "2025-03": 0.58, "2025-06": 0.63, "2025-09": 0.64, "2025-12": 0.62, "2026-03": 0.54, "2026-06": 0.62,
EPS CAGR: 3.59%
EPS Trend: 82.7%
Last SUE: 1.00
Qual. Beats: 1
Revenue Revenue of QGEN over the last years for every Quarter: 2021-09: 534.745, 2021-12: 582.398, 2022-03: 628.391, 2022-06: 515.512, 2022-09: 499.631, 2022-12: 497.984, 2023-03: 485.398, 2023-06: 494.857, 2023-09: 475.894, 2023-12: 509.162, 2024-03: 458.796, 2024-06: 496.347, 2024-09: 501.869, 2024-12: 521.202, 2025-03: 483.456, 2025-06: 533.54, 2025-09: 532.583, 2025-12: 540.42, 2026-03: 492.32, 2026-06: 535.04,
Rev. CAGR: 3.36%
Rev. Trend: 93.9%
Last SUE: 1.15
Qual. Beats: 1

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Seasonality 11.7 years of data

Jan +1.7% 18
Feb -3.5% 23
Mar +0.4% 5
Apr -1.6% 21
May +2.1% 44
Jun +0.8% 8
Jul +4.5% 46
Aug -0.8% 8
Sep -3.0% 53
Oct -5.3% 13
Nov +1.1% 2
Dec +0.6% 16

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: QGEN Qiagen

Qiagen N.V. is a Netherlands-based life sciences company founded in 1984 and headquartered in Venlo that provides sample to insight solutions, converting biological materials into molecular insights for customers worldwide. The company operates within the GICS Health Care sector, specifically the Life Sciences Tools & Services sub-industry, and serves the molecular diagnostics and life sciences markets.

Its portfolio spans consumables and instruments across several workflows, including nucleic acid stabilization and purification kits, immune response assays (such as interferon-gamma release assays for TB testing), oncology and sexual/reproductive health assays, research and digital PCR solutions, NGS library prep and gene panels, and DNA methylation analysis. These consumables are paired with Qiagens own instruments for nucleic acid purification, PCR, and integrated one-step molecular analysis.

In addition to physical products, Qiagen offers bioinformatics solutions and sequence-based forensic genetic genealogy services, and provides software-as-a-service offerings. The business model is built around selling proprietary consumables that are designed to run on its branded instruments, creating an integrated razor-and-blade revenue structure typical of life sciences tools providers.

Headlines to Watch Out For
  • COVID-19 revenue rolloff pressures top-line growth comparisons
  • QIAstat-Dx respiratory panel adoption accelerates hospital testing
  • China demand weakness weighs on life sciences tools revenue
Piotroski VR-10 (Strict) 6.5
Net Income: 409.3m TTM > 0 and > 6% of Revenue
FCF/TA: 0.08 > 0.02 and ΔFCF/TA -0.92 > 1.0
NWC/Revenue: 51.19% < 20% (prev 33.86%; Δ 17.33% < -1%)
CFO/TA 0.11 > 3% & CFO 654.5m > Net Income 409.3m
Net Debt (1.01b) to EBITDA (785.4m): 1.28 < 3
Current Ratio: 2.85 > 1.5 & < 3
Outstanding Shares: last quarter (207.8m) vs 12m ago -4.75% < -2%
Gross Margin: 61.82% > 18% (prev 62.97%; Δ -1.14% > 0.5%)
Asset Turnover: 35.86% > 50% (prev 35.03%; Δ 0.83% > 0%)
Interest Coverage Ratio: 12.68 > 6 (EBIT TTM 499.9m / Interest Expense TTM 39.4m)
Altman Z'' 4.72
A: 0.18 (Total Current Assets 1.66b - Total Current Liabilities 581.4m) / Total Assets 5.89b
B: 0.48 (Retained Earnings 2.81b / Total Assets 5.89b)
C: 0.09 (EBIT TTM 499.9m / Avg Total Assets 5.86b)
D: 1.33 (Book Value of Equity 3.36b / Total Liabilities 2.53b)
Altman-Z'' = 4.72 = AA
Beneish M -2.96
DSRI: 1.00 (Receivables 399.1m/385.8m, Revenue 2.10b/2.04b)
GMI: 1.02 (GM 62.97% / 61.82%)
AQI: 1.05 (AQ_t 0.56 / AQ_t-1 0.54)
SGI: 1.03 (Revenue 2.10b / 2.04b)
TATA: -0.04 (NI 409.3m - CFO 654.5m) / TA 5.89b)
Beneish M = -2.96 (Cap -4..+1) = A
What is the price of QGEN shares?

As of October 10, 2026, the stock is trading at USD 45.38 with a total of 1,255,460 shares traded. Over the past week, the price has changed by +1.41%, over one month by +6.78%, over three months by +8.07% and over the past year by +2.81%.

Current recommended Stop Loss: 43.00 (which is 5.2% or 1.7 ATR below the current price).

Is QGEN a buy, sell or hold?

Qiagen has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold QGEN.

  • StrongBuy: 4
  • Buy: 4
  • Hold: 8
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the QGEN price?
Analysts Target Price 46.3 2%
Qiagen (QGEN) - Fundamental Data Overview as of 07 October 2026
Market Cap USD = 9.46b (9.46b USD * 1.0 USD.USD)
P/E Trailing = 23.2437
P/E Forward = 13.5318
P/S = 4.5018
P/B = 2.6869
P/EG = 1.1661
Revenue TTM = 2.10b USD
EBIT TTM = 499.9m USD
EBITDA TTM = 785.4m USD
Long Term Debt = 1.63b USD (from longTermDebt, last quarter)
Short Term Debt = 16.5m USD (from shortTermDebt, last quarter)
Debt = 1.80b USD (from shortLongTermDebtTotal, last quarter) + Leases 157.9m
Net Debt = 1.01b USD (calculated: Debt 1.80b - CCE 793.5m)
Enterprise Value = 10.5b USD (9.46b + Debt 1.80b - CCE 793.5m)
Interest Coverage Ratio = 12.68 (Ebit TTM 499.9m / Interest Expense TTM 39.4m)
EV/FCF = 23.37x (Enterprise Value 10.5b / FCF TTM 447.7m)
FCF Yield = 4.28% (FCF TTM 447.7m / Enterprise Value 10.5b)
FCF Margin = 21.32% (FCF TTM 447.7m / Revenue TTM 2.10b)
Net Margin = 19.49% (Net Income TTM 409.3m / Revenue TTM 2.10b)
Gross Margin = 61.82% ((Revenue TTM 2.10b - Cost of Revenue TTM 801.8m) / Revenue TTM)
Gross Margin QoQ = 63.62% (prev 62.89%)
Tobins Q-Ratio = 1.78 (Enterprise Value 10.5b / Total Assets 5.89b)
Interest Expense / Debt = 2.19% (Interest Expense 39.4m / Debt 1.80b)
Taxrate = 11.37% (52.5m / 461.8m)
NOPAT = 443.1m (EBIT 499.9m * (1 - 11.37%))
Current Ratio = 2.85 (Total Current Assets 1.66b / Total Current Liabilities 581.4m)
Debt / Equity = 0.54 (Debt 1.80b / totalStockholderEquity, last quarter 3.36b)
Debt / EBITDA = 1.28 (Net Debt 1.01b / EBITDA 785.4m)
Debt / FCF = 2.25 (Net Debt 1.01b / FCF TTM 447.7m)
Total Stockholder Equity = 3.53b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.99% (Net Income 409.3m / Total Assets 5.89b)
RoE = 11.60% (Net Income TTM 409.3m / Total Stockholder Equity 3.53b)
RoCE = 9.70% (EBIT 499.9m / Capital Employed (Equity 3.53b + L.T.Debt 1.63b))
RoIC = 8.49% (NOPAT 443.1m / Invested Capital 5.22b)
WACC = 6.32% (E(9.46b)/V(11.3b) * Re(7.16%) + D(1.80b)/V(11.3b) * Rd(2.19%) * (1-Tc(0.11)))
Discount Rate = 7.16% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -92.47 | Cagr: -3.77%
[DCF] Terminal Value 73.99% ; FCFF base≈467.1m ; Y1≈430.5m ; Y5≈384.0m
[DCF] Fair Price = 24.61 (EV 6.09b - Net Debt 1.01b = Equity 5.08b / Shares 206.5m; r=8.35% [WACC [floored]]; 5y FCF grow -9.80% → 2.50% )
EPS Correlation: 82.71 | EPS CAGR: 3.59% | SUE: 1.00 | # QB: 1
Revenue Correlation: 93.93 | Revenue CAGR: 3.36% | SUE: 1.15 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.62 | Chg30d=+0.45% | Revisions=-62% | Analysts=9
EPS current Year (2026-12-31): EPS=2.43 | Chg30d=+0.00% | Revisions=-25% | GrowthEPS=+2.3% | GrowthRev=+2.2%
EPS next Year (2027-12-31): EPS=2.61 | Chg30d=+0.14% | Revisions=+25% | GrowthEPS=+7.4% | GrowthRev=+5.1%
[Analyst] Revisions Ratio: -50% (up=1, down=6)